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Introduction 
Aortic graft infection is among the most dreaded com- 
plications in vascular surgery. Regardless of man- 
agement, it leads to high morbidity and mortality. 
Successful treatment traditionally involves removal of 
the infected prosthesis and revascularisation of the 
lower extremities by an extra-anatomic bypass. >3 Ini- 
tial reviews of institutional series of patients with 
aortic graft infection emphasised the immediate post- 
operative mortality and morbidity. 
The long-term success of conventional treatment is
measured in terms of patient survival, limb salvage 
and the abscence of complications related to graft 
excision, for example aortic stump blow-out. 4-1° 
As a treatment option for selected patients - no 
clinical evidence of septicaemia or retroperitoneal pur- 
ulent collections and no bacteriological evidence of 
pseudomonas infection- many vascular surgeons now 
prefer in situ graft replacement of an infected aortic 
graft. ~>~9 Its long-term success hould be measured in 
terms of persistent retroperitoneal infections that can 
develop even years after graft replacement. Late in- 
fectious complications most commonly arise in 
patients with primary graft infections caused by the 
less virulent micro-organism, for example coagulase- 
negative Staphylococcus epidermidis. 19 Hence the need 
for clinical and diagnostic imaging follow-up for re- 
liable retroperitoneal surveillance. Newly introduced 
functional diagnostic techniques capable of detecting 
graft infections in their early stages, notably leukocyte- 
labelled 99m HMPAO Technetium Scintigraphy (99m- 
Tc), seem to meet this requirement. 2°-22 
We report a long-term follow-up (mean 37 months) 
of 18 patients, nine with an aortoenteric erosion (AEE) 
* Please address all correspondence to: F. Speziale, University of 
Rome, "La Sapienza" 00161, Rome, Italy. 
and nine with a perigraft infection (PGI), who under- 
went excision of the infected aortofemoral graft and in 
situ polytetrafluoroethylene (PTFE) graft replacement. 
Materials and Methods 
We retrospectively reviewed the clinical data of all 
patients who underwent in situ graft replacement for 
AEE and PGI at the Department of Vascular Surgery, 
University of Rome, "La Sapienza" between November 
1989 and March 1995. Data analysed included original 
graft reconstruction, clinical presentation, preoperative 
diagnosis, operative management, bacteriological cul- 
tures of explanted material, early and late com- 
plications, survival and limb salvage rate. 
Recurrence or persistent infection were defined as 
the new onset of clinical symptoms (fever, leu- 
kocytosis, groin sinus tract) or imaging evidence of 
infection (99m-Tc scan leukocytes uptake, computed 
tomography (CT) detected retroperitoneal collection). 
A mean 37 month follow-up (8-59 months) was ob- 
tained from 3-monthly clinical and biochemical as- 
sessments (erythrocyte sedimentation rate, white 
blood cell count), a 6-monthly 99m-Tc scan for the first 
year and yearly thereafter. Patients with uncertain 
99m-Tc scan findings underwent a CT scan. 
Results 
During the 4.5-year study period, 18 patients (17 men 
and one woman, mean age of 64.7 years, range 31-77 
years) underwent in situ PTFE graft replacement, nine 
patients for AEE and nine patients PGI. Eleven patients 
had their original aortic reconstruction at our de- 
partment and seven elsewhere. Eight (44.4%) had ori- 
ginally undergone surgery for occlusive arterial 
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disease, 10 (55.6%) for infrarenal aortic aneurysms, one 
a ruptured aneurysm. All original surgical procedures 
were done with knitted Dacron grafts, under peri- 
operative antibiotic overage. Twelve patients had ori- 
ginally received aortomonofemoral or aortobifemoral 
bypass grafts; five had aortoaortic grafts and one an 
aortobi-iliac graft. All patients had an uncomplicated 
postoperative course. The mean interval between graft 
placement and diagnosis of graft infections was 46 
months (range 6-77). 
Clinical examination showed that all patients were 
haemodynamically stable. None required emergency 
treatment. The most frequent symptom was in- 
termittent fever (12 patients, 66.6%), seven patients 
reported gastrointestinal b eeding: four had occult 
faecal blood and three referred a single episode of 
melaena with an average onset 20 days before ad- 
mittance. Eleven patients (61.1%) also had groin symp- 
toms: five cases (41.6%) cutaneous sinus tracts, three 
(25%) abscesses, and three (25%) false anastomotic 
aneurysms. CT scans, obtained in all subjects at ad- 
mittance, showed that 13 patients (72.2%) had evidence 
of periprosthetic infection (gas bubbles, periprosthetic 
inflammatory reactions) but none of them had gross 
retroperitoneal collections. Magnetic resonance im- 
aging (MRI), obtained in eight cases, showed that six 
patients (75%) had evident signs of prosthetic graft 
infection. In all 18 patients (100%), scintigraphy with 
99m-Tc scan revealed a pathological leukocyte ac- 
cumulation along the entire graft. Arteriograms were 
obtained in all patients for planning surgical treatment. 
The seven patients who had previous gastrointestinal 
bleeding underwent upper gastrointestinal endoscopy 
(UGIE) as the first diagnostic intervention. Six of them 
(85.7%) had aorto-enteric erosions in the third or fourth 
portion of the duodenum. 
The operative procedure comprised excision of the 
prosthetic graft and immediate in situ replacement 
with a standard PTFE graft. None of the infected 
prosthetic grafts adhered closely to the surrounding 
tissues, none had unduly large purulent collections, 
and none of the proximal aortic anastomoses showed 
signs of suture-line dehiscence. Nine patients had 
"AEEs. In these patients, before vascular surgery, the 
duodenal lesion was repaired, in six cases by duodenal 
deepening with a simple suture and in three cases 
with a resection of the third part of the duodenum 
and end-to-end intestinal anastomosis. Before in situ 
placement of the PTFE graft, the surrounding necrotic 
tissues were debrided as thoroughly as possible and 
the field washed repeatedly with an antiseptic solution 
containing 2% povidine-iodine. In patients with AEE, 
we isolated the new prosthesis from the duodenum 
by inserting an omental wrap. All patients received 
intravenous antibiotic therapy for 6 weeks post- 
operatively, followed by a 2-week course of oral 
therapy. 
Two of the 18 patients died during the postoperative 
course: the first on the second postoperative day after 
a myocardial infarction and the other, a patient with an 
AEE, on postoperative day 19 because of haemorrhagic 
shock. Autopsy revealed ehiscence of the proximal 
anastomosis. None of the remaining 16 operations 
resulted in perioperative d aths, none of the prosthetic 
branches became thrombosed and no amputations 
were needed. During a mean follow-up of 37 months 
(range 8-59 months), none of our 16 surviving patients 
had infectious complications related to the new graft. 
Preoperative 99m-Tc scan obtained 6 months after in 
situ replacement showed that 13 patients (81.2%) had 
complete disappearance of leukocyte accumulations. 
The remaining three patients (18.8%) had reduced 
accumulations. Repeat 12 month postoperative scans 
showed no further leukocyte uptake along the grafts. 
Two patients had thrombectomy of a graft limb, 4 and 
12 months after replacement. One patient died of a 
lung neoplasm after graft replacement but had no 
evidence of graft-related complications. 
Discussion 
The most widely accepted surgical management option 
for aortofemoral graft infections consists of removal 
of the infected prosthesis followed by aortic ligation 
and extra-anatomic revascularisation of the lower 
limbs. This procedure has gradually improved results 
so that current perioperative mortality ranges from 14 
to 29%, the incidence of amputation from 13 to 29%. 4-9 
But it also puts patients at risk for late complications 
linked to aortic ligation, wound dehiscence or aortic 
pseudoaneurysms. The few series with a long-term 
follow-up (35-60 months) also report a 10-15% in- 
cidence of retroperitoneal reinfection. 1° The extra-ana- 
tomic bypass procedure alone places patients at 
generic risk of graft-related complications (thrombosis, 
infection and embolisation) that necessitate am- 
putation. 23'24 The risk of thrombosis or a reinfected 
axillofemoral bypass ranges from 5 to 30%. In a series 
of 51 patients with PGI and 33 with graft-enteric 
fistula and a 5-year follow-up, O'Hara et al. 6 reported 
a survival of 18% and an amputation rate of 27%. They 
also noted that although perigraft infection patients 
had significantly greater 30-day survival curves than 
patients with graft-enteric fistula (85% vs. 49%), their 
1-year survival curves became similar (47% vs. 35%). 
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In a series of 28 patients, with a mean 44-month follow- 
up, Yeager et al. 7 reported an extra-anatomic bypass 
reinfection rate of 22% and an amputation rate of 24%. 
In a 35-month follow-up of 30 patients who survived 
aortic ligation and extra-anatomic bypass, Quinones- 
Baldrich et al. 8 reported a mortality of 20% and an 
amputation rate of 22%. 
Encouraged by the good outcome obtaIned by 
others  25"26 we have used in situ graft replacement as an 
alternative to graft removal. Current evidence suggests 
that the in situ procedure is clinically contraindicated 
in patients with septicaemia or retroperitoneal bs- 
cesses, n'13'15 and bacteriologically contraindicated in all 
patients with pseudomonas infections. ~s'~6 Long-term 
results from studies using these indications uggest a
graft-reinfection rate ranging from 5 to 14%. Re- 
infections developed in patients with aortobifemoral 
bypasses and localised groin symptoms, who had 
undergone replacement of the clinically infected graft 
branch aloneY '19 From the technical viewpoint, we 
based our decision to perform total graft removal less 
on clinical criteria than on 99m-Tc scan data. Even in 
patients who had clinical symptoms localised to the 
groin, some scans clearly showed leukocyte uptake 
also in the proximal anastomosis, and bacteriological 
cultures ubsequently confirmed these findings. Rad- 
ical surgery may explain why in our patients the 
recurrent infections commonly reported by others did 
not develop. 
Although the ideal material for in situ replacement 
grafts remains controversial, most vascular surgeons 
have used Dacron grafts, 12-14 and recent papers have 
described the experimental nd clinical use of Dacron 
prostheses impregnated with rifampicin. ~7'27 In 1991, 
Bahnini et al. 28 reported the first case of an infected 
aortic graft replaced with a prosthesis made from the 
aorta taken from a cadaver. In 1993 they reported 
promising results obtained using this method in a 
series of 58 artic graft infections. 29 The immediate 
results after homologous tissue transplantation i - 
dicated a perioperative mortality rate of 13.8% with 
no major amputation; during a 19.6-month follow-up 
(range 14-33 months) only one patient died because 
of reinfection, whereas 24% of the patients had com- 
plications (including aortoiliac dilatation and ilio- 
femoral steno-occlusive lesions) directly related to the 
type of homologous graft material. If future research 
solves the immunological problems thought re- 
sponsible for complications, then synthetic grafts 
might be abandoned in favour of homologous grafts. 
In 1995, Nevelsteen et al. 3° reported autogenous re- 
construction with the superficial femoral vein in 12 
patients with prosthetic infection after aorto (ilio)- 
femoral grafting. A mean 17-month follow-up showed 
no reinfections, one occluded graft, and minimal dis- 
ability from removal of the deep veins. Although 
autogenous reconstruction promises to save life and 
limb, a longer period of follow-up is required to study 
the long-term behaviour of these grafts and to allow 
definitive comparison with the more conventional p- 
proaches. Since 1989 we have used grafts made of 
PTFE because the bacteria that most commonly cause 
primary graft infections adhere much less easily to 
PTFE than to Dacron. 31 
Our analysis of postoperative morbidity showed 
that none of our patients needed limb amputation; in 
two patients who developed a graft limb thrombosis, 
thrombectomy followed by anticoagulant therapy re- 
solved the problem. One patient died of a neoplasm 
44 months after graft replacement and had no signs of 
reinfection. During the 37-month follow-up no patient 
had evidence of graft reinfection. The surveillance 
protocol for new grafts implanted in patients under- 
going in situ replacement comprised 3-monthly clinical 
assessment and 6-monthly 99m-Tc scans for the first 
postoperative year and annually thereafter. Of the 
imaging techniques used in the diagnosis of graft 
infections, 99m-Tc scanning seems highly reliable and 
will detect bacterial contamination already in the first 
months after original graft implantation. 21Pathogen- 
specific antibiotic therapy started as soon as possible 
and prolonged postoperatively is essential to prevent 
reinfection. Our patients receive intravenous anti- 
biotics for 6 weeks, and oral therapy for at least 2 
weeks. Serum samples are tested regularly to monitor 
the efficacy of therapy. 
Conclusions 
An infected aortic graft remains an unwelcome vent. 
Nonetheless, urgical treatment offers far better pro- 
spects now than it did in the past. The improved 
surgical outcome has shifted attention to problems 
related to the long-term surveillance of surviving 
patients. After conventional surgery and in situ re- 
placement, a meticulous retroperitoneal surveillance 
protocol is needed to detect reinfections (including 
pseudoaneurysms of the aortic stump and purulent 
fluid collections) in their early stages before re- 
troperitoneal bleeding develops. Of the currently 
available techniques, leukocyte-labelled 99m-Tc scin- 
tigraphy has proved diagnostically reliable and fulfills 
this purpose well. The final question is, how long do 
these patients need surveillance? Long follow-up is 
crucial in those with infections caused by low-vir- 
ulence micro-organisms, for example coagulase-neg- 
ative Staphylococcus epidermidis. 
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